Neville Rodie & Shaw’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.7M | Sell |
17,226
-3,564
| -17% | -$3.64M | 1.34% | 19 |
|
|
2026
Q1 | $19.1M | Buy |
20,790
+1,622
| +8% | +$1.64M | 1.39% | 19 |
|
|
2025
Q4 | $20.6M | Buy |
19,168
+5,041
| +36% | +$4.82M | 1.45% | 19 |
|
|
2025
Q3 | $10.8M | Sell |
14,127
-1,861
| -12% | -$1.38M | 0.78% | 32 |
|
|
2025
Q2 | $12.5M | Buy |
15,988
+897
| +6% | +$697K | 0.92% | 30 |
|
|
2025
Q1 | $12.5M | Buy |
15,091
+60
| +0.4% | +$49.9K | 0.98% | 30 |
|
|
2024
Q4 | $11.6M | Buy |
15,031
+97
| +0.6% | +$80.3K | 0.85% | 34 |
|
|
2024
Q3 | $13.2M | Sell |
14,934
-439
| -3% | -$395K | 0.97% | 30 |
|
|
2024
Q2 | $13.9M | Buy |
15,373
+207
| +1% | +$166K | 1.06% | 25 |
|
|
2024
Q1 | $11.8M | Buy |
15,166
+716
| +5% | +$510K | 0.9% | 32 |
|
|
2023
Q4 | $8.42M | Buy |
14,450
+1,420
| +11% | +$829K | 0.69% | 39 |
|
|
2023
Q3 | $7M | Buy |
13,030
+460
| +4% | +$237K | 0.62% | 40 |
|
|
2023
Q2 | $5.89M | Buy |
12,570
+9,940
| +378% | +$4.17M | 0.51% | 49 |
|
|
2023
Q1 | $903K | Buy |
2,630
+690
| +36% | +$233K | 0.08% | 137 |
|
|
2022
Q4 | $710K | Buy |
1,940
+665
| +52% | +$236K | 0.07% | 148 |
|
|
2022
Q3 | $412K | Buy |
1,275
+75
| +6% | +$23.8K | 0.04% | 184 |
|
|
2022
Q2 | $389K | Hold |
1,200
| – | – | 0.03% | 196 |
|
|
2022
Q1 | $351K | Hold |
1,200
| – | – | 0.03% | 216 |
|
|
2021
Q4 | $331K | Hold |
1,200
| – | – | 0.02% | 217 |
|
|
2021
Q3 | $277K | Hold |
1,200
| – | – | 0.02% | 224 |
|
|
2021
Q2 | $275K | Hold |
1,200
| – | – | 0.02% | 227 |
|
|
2021
Q1 | $224K | Hold |
1,200
| – | – | 0.02% | 240 |
|
|
2020
Q4 | $203K | Buy |
+1,200
| New | +$179K | 0.02% | 242 |
|
|
2019
Q3 | – | Sell |
-2,200
| Closed | -$244K | – | 242 |
|
|
2019
Q2 | $244K | Sell |
2,200
-33
| -1% | -$3.89K | 0.03% | 219 |
|
|
2019
Q1 | $290K | Buy |
2,233
+33
| +2% | +$4.01K | 0.03% | 207 |
|
|
2018
Q4 | $255K | Hold |
2,200
| – | – | 0.03% | 201 |
|
|
2018
Q3 | $236K | Buy |
+2,200
| New | +$220K | 0.02% | 229 |
|
|
2015
Q3 | – | Sell |
-2,600
| Closed | -$217K | – | 261 |
|
|
2015
Q2 | $217K | Buy |
+2,600
| New | +$198K | 0.02% | 250 |
|
|
2013
Q4 | – | Sell |
-66,610
| Closed | -$3.35M | – | 261 |
|
|
2013
Q3 | $3.35M | Sell |
66,610
-8,750
| -12% | -$458K | 0.39% | 69 |
|
|
2013
Q2 | $3.7M | Buy |
+75,360
| New | +$4.1M | 0.45% | 62 |
|
Other funds holding LLY
SC
ONB
GIM
Neville Rodie & Shaw's LLY Position: Q2 2026 in Review
Neville Rodie & Shaw reduced its Eli Lilly (LLY) stake by 17% in Q2 2026, selling an estimated $3.64M and leaving 17,226 shares worth $20.7M. The position accounts for 1.34% of the portfolio, ranked #19.
Neville Rodie & Shaw first reported a position in LLY in Q2 2013 and has held it in 30 quarters since. 1,844 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Neville Rodie & Shaw held 17,226 shares of Eli Lilly worth $20.7M as of Q2 2026.
- Neville Rodie & Shaw sold 3,564 Eli Lilly shares in Q2 2026, an estimated $3.64M.
- Eli Lilly made up 1.34% of Neville Rodie & Shaw's portfolio in Q2 2026, its #19 holding.
- Neville Rodie & Shaw first reported a position in Eli Lilly in Q2 2013 and has held it in 30 quarters since.
- 1,844 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Neville Rodie & Shaw's 13F filing for Q2 2026, filed 6 Jul 2026.